Symbol="ALLO"
AssetType="Common Stock"
Name="Allogene Therapeutics Inc"
Description="Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California."
CIK="1737287"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="689833000"
EBITDA="-340416992"
PERatio="None"
PEGRatio="None"
BookValue="4.064"
DividendPerShare="0"
DividendYield="0"
EPS="-2.27"
RevenuePerShareTTM="0.002"
ProfitMargin="0"
OperatingMarginTTM="-1515.07"
ReturnOnAssetsTTM="-0.259"
ReturnOnEquityTTM="-0.486"
RevenueTTM="234000"
GrossProfitTTM="243000"
DilutedEPSTTM="-2.27"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.148"
AnalystTargetPrice="17.28"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4133.63"
PriceToBookRatio="1.508"
EVToRevenue="2674.75"
EVToEBITDA="-2.221"
Beta="0.739"
num_52WeekHigh="17.49"
num_52WeekLow="4.3"
num_50DayMovingAverage="5.33"
num_200DayMovingAverage="6.78"
SharesOutstanding="145842000"
DividendDate="None"
ExDividendDate="None"
symbol="ALLO"
open="5.14"
high="5.15"
low="4.71"
price="4.73"
volume="2022226.00"
latest_trading_day="2023-07-27"
previous_close="5.06"
change="-0.33"
change_percent="-6.5217%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="78"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="22"
Volume_recent_avg="2411085"
Change_recent_avg="-0.02"
Delta_recent_avg="0.35"
Variance_recent_avg="0.18"
Change_ratio_recent_avg="-0.43"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="22"
Aroon_momentum_negative="78"
image_negative_thumbnail_id_1="500"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0105.jpeg"
image_negative_thumbnail_id_2="496"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0109.jpeg"
image_neutral_thumbnail_id_1="549"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0050.jpeg"
image_neutral_thumbnail_id_2="541"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0058.jpeg"
image_positive_thumbnail_id_1="1009"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0171.jpeg"
image_positive_thumbnail_id_2="704"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0004.jpeg"
image_professor_thumbnail_id_1="1190"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0024.jpeg"
image_professor_thumbnail_id_2="1191"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0025.jpeg"
